Flubrix spray oromukozn. solution 8.75mg/doza fl. 15 ml

Flubrix Spray for short-term symptomatic simplification of an acute pain in a throat at adults.

Structure

• active ingredient: flurbiprofen;
• 1 dose contains flurbiprofen 8.75 mg;
• other components: betadex; sodium hydrophosphate, dodecahydrate; citric acid, monohydrate; methylparahydroxybenzoate (E218); propilparagidroksibenzoat (E216); sodium saccharin; hydroxypropyl betadex; sodium hydroxide; mint fragrance; cherry fragrance; N, 2.3-trimetil-2-isopropyl-butanamid; water is purified.

Contraindication

Hypersensitivity to a flurbiprofen or any of other components of medicine.

Reaction of hypersensitivity (for example, bronchial asthma, a bronchospasm, rhinitis, a Quincke's edema or a small tortoiseshell) after use of acetylsalicylic acid or other non-steroidal anti-inflammatory medicaments (NPVS).

Recurrent peptic ulcer / bleeding in the anamnesis or in an aggravation phase (two and more episodes confirmed with characteristic clinical manifestations) and intestines ulcers.

Gastrointestinal bleeding in the anamnesis or perforation, colitis with a heavy course, the hemorrhagic or hemopoietic frustration connected with the previous therapy of NPVS.

Last trimester of pregnancy.

Heavy heart failure, heavy renal failure or heavy liver failure.

Children's age (up to 18 years).

Side reactions

cases of reactions of hypersensitivity to NPVS, namely:

• nonspecific allergic reactions and anaphylaxis;
• reactivity of airways, for example bronchial asthma, exacerbation of bronchial asthma, bronchospasm, short wind;
• various skin reactions, for example an itch, urticaria, a Quincke's edema less often — exfoliative and bullous dermatitis (including an epidermal necrolysis and a multiformny erythema).

Due to the treatment of NPVS it was reported about such phenomena as hypostasis, arterial hypertension and heart failure. There are not enough data to exclude such risk in case of use of spray for an oral cavity, solution of a flurbiprofen.

Route of administration

For oromukozny application. Only for short-term application. The adult applies 1 dose (3 squirts) on a back wall of an oral cavity each 3–6 hours if necessary, but no more than 5 doses a day.

at dispersion.

does not recommend to apply medicine more than 3 days.

Before the first application should activate the spray. For this purpose it is necessary to turn a nozzle from itself aside and to press a cap at least four times until spray begins to be sawn in the form of a transparent uniform cloud. Thus, medicine will get to the spray and spray will be ready to application.

Before application of each following dose should turn a nozzle from itself aside, to press a cap at least once and to be convinced that spray is sawn in the form of a transparent uniform cloud. Every time before application it is necessary to check dispersion.

to Apply the low effective dose necessary for control of symptoms, during the shortest time.

to Patients of advanced age needs to apply the minimum possible effective dose as soon as possible.

Undesirable effects can be reduced by

Feature of application

Use during pregnancy or feeding by a breast

Pregnancy. The inhibition of synthesis of prostaglandins can have negative impact on pregnancy and/or development of an embryo/fruit. During the first and second trimester of pregnancy it is not necessary to use flurbiprofen.

during ІІІ a pregnancy trimester as all inhibitors of synthesis of prostaglandins can provoke:

• at a fruit: cardiopulmonary toxicity (with premature closing of an arterial channel and development of pulmonary hypertensia), a renal failure that can progress to a renal failure, small or a hydramnion;
• at mother and the newborn: long bleeding in connection with anti-aggregation effect which can be shown even at very low doses; inhibition of reductions of muscles of a uterus that leads to a delay or prolongation of childbirth.

Feeding by a breast. The insignificant quantity of a flurbiprofen was revealed in maternal milk, but negative impact of a flurbiprofen on the newborns who are on breastfeeding was not revealed. It is necessary to avoid use of medicine when feeding by a breast.

Safety and efficiency of use of Flubrix medicine spray are not established to children (up to 18 years) by

.

Ability to influence speed of response at control of motor transport or other mechanisms

At application of NPVS the dizziness, drowsiness, fatigue and visual disturbances are possible

. At emergence of these side effects it is not recommended to steer motor transport and other mechanisms.

Overdose

Symptoms. Most of the patients who accepted clinically significant amounts of non-steroidal anti-inflammatory medicaments can have only a nausea, vomiting, pain in epigastric area or is very rare — diarrhea. There can also be a sonitus, headaches and bleeding from a digestive tract. In more serious poisoning there can be toxic damages of the central nervous system in the form of drowsiness, sometimes excitement, a disorder of vision, a disorientation or a coma. Sometimes at patients spasms are observed. In a serious poisoning there can be a metabolic acidosis and continue a prothrombin time owing to impact on blood-coagulation factors. The sharp renal failure and injury of a liver can develop. At patients with bronchial asthma the aggravation of a course of the disease can be observed.

Treatment. Treatment can be symptomatic and supporting and also to include clarification of airways, monitoring of indicators of warm activity and key indicators of activity before achievement of a steady state. Oral administration of activated carbon or gastric lavage, if necessary correction of electrolytes of serum, in case of the address of the patient during 1 h after use of potentially toxic amount of medicine is recommended. In case of bronchial asthma it is necessary to apply bronchodilators. There is no specific antidote to a flurbiprofen.

Interaction with other medicines and other types of interactions

Should avoid simultaneous application of a flurbiprofen from:

• acetylsalicylic acid if acetylsalicylic acid was not appointed by the doctor in low doses (not higher than 75 mg/days) as it can lead to emergence of side reactions;
• other NPVS, including selection inhibitors of cyclooxygenase-2 (TsOG-2) as it increases risk of side effects (especially undesirable reactions from digestive tract, such as ulcers and bleedings).

Alcohol. The risk of emergence of undesirable reactions, especially bleedings in digestive tract increases.

to Store

at a temperature not higher than 25 S. Hranit out of children's reach. Not to store in the fridge and not to freeze.

Expiration date – 2 years.

not to use medicament after the expiration date specified on packing.

Expiration date after the first disclosure of a bottle – 6 months.